A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis

@article{Kimura2014APC,
  title={A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis},
  author={Hiroshi Kimura and Nobuhisa Kanahara and Naoya Komatsu and Minoru Ishige and Katsumasa T Muneoka and Masayuki Yoshimura and Hiroshi Yamanaka and Tomotaka Suzuki and Hideki Komatsu and Tsuyoshi Sasaki and Tasuku Hashimoto and Tadashi Hasegawa and Akihiro Shiina and Masatomo Ishikawa and Yoshimoto Sekine and Tetsuya Shiraishi and Hiroyuki Watanabe and Eiji Shimizu and Kenji Hashimoto and Masaomi Iyo},
  journal={Schizophrenia Research},
  year={2014},
  volume={155},
  pages={52-58}
}
  • Hiroshi Kimura, Nobuhisa Kanahara, +17 authors Masaomi Iyo
  • Published in Schizophrenia Research 2014
  • Psychology, Medicine
  • OBJECTIVE Dopamine supersensitivity psychosis (DSP) is considered to be one cause of treatment-resistant schizophrenia (TRS). The authors investigated the efficacy of risperidone long-acting injections (RLAI) in patients with TRS and DSP. METHOD This is a multicenter, prospective, 12-month follow-up, observational study that included unstable and severe TRS patients with and without DSP. 115 patients with TRS were recruited and divided into two groups according to the presence or absence of… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 18 CITATIONS

    Treatment-resistant schizophrenia: challenges and implications for clinical practice.

    VIEW 8 EXCERPTS
    CITES BACKGROUND & RESULTS
    HIGHLY INFLUENCED

    Treatment of Clozapine Nonresponders

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 45 REFERENCES

    "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.

    VIEW 1 EXCERPT
    HIGHLY INFLUENTIAL

    A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

    VIEW 2 EXCERPTS
    HIGHLY INFLUENTIAL

    Course of treatment response in first-episode and chronic schizophrenia.

    VIEW 1 EXCERPT
    HIGHLY INFLUENTIAL

    Time course and biologic correlates of treatment response in first-episode schizophrenia.

    VIEW 1 EXCERPT
    HIGHLY INFLUENTIAL